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TO THE EDITOR
It is generally accepted that EVI1, inappropriately expressed in hematopoietic cells after rearrangements of the 3q26 chromosomal band, is also aberrantly expressed in leukemic samples without 3q26 abnormality, which is the site of the EVI1 locus. 1, 2 EVI1 was initially described in murine myeloid leukemia, where it was shown to be activated by proviral insertion in the Evi-1 common integration site. 3 More recently, EVI1 was shown to be part of a fusion gene named MDS1-EVI1, which results from the in-frame splicing of EVI1 and MDS1, a gene mapped 150-300 kb upstream of EVI1. 4 Based on Fears et al data, 4 the sequence of EVI1 after the MDS1-EVI1 splice junction starts with the second exon of EVI1 as reported by Morishita et al 5 and continues to the end of Morishita's EVI1 cDNA. Hence, EVI1 and MDS1-EVI1 transcripts share a strong homology in nucleotide sequences, the two transcripts differing only at their extreme 5 0 ends where they have unique sequences. 4 The amplified products that have been detected, using common primers, by several authors 1,2 in leukemic samples without 3q26 rearrangement could therefore belong to MDS1-EVI1 rather than EVI1. To shed some light on this issue, we designed primers specific for the 5 0 end of both genes. Taking advantage of an RNA collection, we performed a discriminating screening between MDS1-EVI1 and EVI1 by RT-PCR in 34 samples obtained from patients with myeloid neoplasms (Table 1) referred to our laboratory for routine cytogenetic and molecular diagnoses (BCR-ABL transcript detection). Previous analyses had proved all 34 specimens to be positive by RT-PCR, using primers described in the literature, 5 for the common distal 3 0 end of MDS1-EVI1 and EVI1, and negative for 3q26 chromosomal band rearrangements by routine conventional and molecular cytogenetics (whole-chromosome painting with a probe specific for chromosome 3). We report that MDS1-EVI1 was expressed in all 34 analyzed cases. In contrast, EVI1 was expressed in only seven patients, concomitantly to the MDS1-EVI1 transcript.
Total RNA was prepared by lysis of bone marrow or peripheral blood mononuclear cells, and nucleic acid extraction was carried out with Trizol reagent. cDNA synthesis was performed using random hexamer primers (Boehringer Mannheim, Meylan, France) with 2.5 mg of total RNA in a total volume of 50 ml following standard procedures. 6 The cDNA samples were then subjected to PCR analysis for the various products using a thermal cycler 480 Applied Biosystems. The amplification reaction mixture contained 1.25 U Taq/50 ml (ampliTaq, Applied Biosystems, 78 St Quentin, France), 250 mM dNTPs (Boehringer Mannheim, Meylan, France), and 1 Â PCR buffer. Sequences, positions of the oligonucleotide primers and probes, as well as cycle conditions used in this study are shown in Figure 1a and Table 2 . To confirm the integrity of the isolated RNA and the correctness of cDNA synthesis, the ubiquitously expressed c-ABL gene was amplified in a separate PCR reaction. Each PCR assay included RNA extracted from K562 cells and HL60 cells as positive and negative controls, respectively. Leukemic cells bearing 3q26 rearrangements, either inv(3)(q21q26) or t(3;21), were also used to confirm the specificity of our set of primers. In addition, RT-PCR reactions without reverse transcriptase or with water rather than input RNA were carried out for each sample as controls of reagent contamination. After amplification, the PCR products were size fractionated by electrophoresis in 2% Nusieve/agarose gel and visualized by ethidium bromide staining. The specificity of the amplification products was confirmed by Southern blot analysis of the amplified fragments after transfer to a nylon membrane and hybridization to specific internal nonisotopic labelled oligoprobes.
The results of the discriminating screening by RT-PCR analyses are summarized in Table 1 . Amplification of the 5 0 end of EVI1, using primers specific for the 5 0 unique nontranslated first exon and for the second translated exon of EVI1 (exon 4), failed to produce, in the majority (27/34) of our cases, the 562 bp product that would be expected based on the sequence data. 5 Contrasting with data reported in the literature, this result would indicate that a full-length EVI1 transcript is absent in these 3q26 rearrangement negative leukemic cases. However, leukemic cells from 7/34 patients did express the 5 0 end of EVI1, as well as the K562 cell line and inv(3)-positive cells used as controls, suggesting that the expression of a fulllength EVI1 RNA occurs in these samples. In addition to the expected 562 bp product, several other 5 0 EVI1 cDNA products were amplified in all seven cases and in the positive controls (Figure 1b) . These fragments were detected on agarose gel and consistently had similar size for all the samples, suggesting that they could be products of variable alternative splice junctions rather than the result of inappropriate priming. Southern blot analysis with internal oligoprobe specific for EVI1 exon 2 (GNC) confirmed that these fragments were products of the EVI1 transcripts (Figure 1b) . A rapid progression of the disease, cytogenetically characterized by the emergence of an abnormal subclone with a 3q26 rearrangement, was noted in 2/7 EVI1 positive cases: a CML case (case 3, Figures 1b and c) progressed to CML-BC with the emergence of an inv(3)(q21q26) 7 months after diagnosis; similarly, the second patient (AML M1 case) relapsed 8 months after diagnosis with a leukemic subclone showing a t(3;8)(q26;p12) in addition to the (9;22) translocation. The 3q26 rearrangements were not present at diagnosis (30 Table 1 Results of the RT-PCR screening allowing discrimination between MDS1-EVI1 and EVI1 RNAs (34 patients with myeloid neoplasms were included in the study) The results of the analysis of three patients (two CML, #3 and #4; and one AML, #5) are also shown. In addition to the expected 562 bp product, several 5 0 EVI1 cDNA products were amplified with primers EVI1UP and EVI1LO. The specificity of these fragments as EVI1 products was confirmed after Southern analysis followed by hybridization to an internal oligoprobe specific for EVI1 exon 2 (GNC, Figure 1a) . (c) Representative Southern blot analysis of RT-PCR experiments for the detection of the MDS1(exon2)-EVI1(exon2) junction (top panel, primers GNA and GNC) and the MDS1(exon1)-EVI1(exon2) junction (bottom panel, primers GNF and GNC). The specificity of the amplified products was assigned by hybridization with specific internal nonisotopic labelled oligoprobes ( Table 2 ). The K562 and HL60 cell lines serve as positive and negative controls, respectively. Each group of PCR reactions included an RT-negative control, in which a sample containing water rather than input RNA was carried out through all steps as control of reagent contamination. Results of three CML cases (cases 1-3) are also shown.
analyzed metaphases). Thus, detection by RT-PCR of a fulllength EVI1 transcript in these two cases preceded apparition of the 3q26 anomaly and overt evolution of the disease.
In contrast, RT-PCR analyses with primers specific for the unique 5 0 end of the gene (GNA, GNF and GNC, Figure 1a ) detected MDS1-EVI1 transcripts in all 34 cases, in the form of amplification products of 431 and 469 bp as expected from Fears' data. 4 These two fragments correspond to exon2-exon2 and exon1-exon2 MDS1-EVI1 junctions, respectively (Figure 1c , top and bottom panels). The expression of MDS1-EVI1 requires splicing of the second exon of MDS1 to the second exon of EVI1. This event involves the transcription of several hundred kb of DNA, but it is apparently a normal event in pancreas and kidney which normally express the MDS1-EVI1 cDNA. 4 The resulting MDS1-EVI1 transcript contains almost the entire MDS1 and the entire coding region of EVI1. 4 This splicing event has also been identified in leukemic cells with t(3;21) and t(3;12). 7, 8 Both rearrangements generate a fusion gene that contains the partner gene at 21q22 or 12p13 (AML1 and ETV6, respectively) fused to the second exon of MDS1-EVI1. Thus, the first MDS1 exon1 is lost. Hence, our finding that all 34 cases we analyzed retain the first exon of MDS1 suggests that these patients express a full-length MDS1-EVI1 transcript rather than an abnormal transcript similar to that observed in t(3;21) and t(3;12) carrying cells. 7, 8 In summary, a discriminating screening is necessary to ascertain EVI1 expression by RT-PCR in myeloid neoplasms. Whereas the expression of a full-length EVI1 transcript may be explained in two cases as the result of clonal expansion of a cell with a 3q26 abnormality, so far we do not have an explanation for the detection of a full-length MDS1-EVI1 in all 34 leukemic samples included in this series. The genomic region that encodes MDS1, MDS1-EVI1, and EVI1 is about 500 kb and it is not known how the differential regulation of these three genes occurs. 1 Deregulation of MDS1-EVI1 expression could be the result of some cryptic genetic event(s) involving promoter(s) of the gene. MDS1-EVI1 overexpression could also result from deregulation of critical gene(s) involved in MDS1-EVI1 transcription control. Finally, 3 0 end transcription of EVI1 (then possibly MDS1-EVI1) has been detected by RT-PCR in mononuclear cells of BM and PB from normal donors, and it has been suggested that the gene could be expressed at a specific stage during normal hematopoiesis. 9 This expression was linked to the CD34 + cell population and early stages of hematopoiesis. 9 Therefore, expression of full-length MDS1-EVI1 RNAs in some myeloid neoplasms characterized by an increased marrow cellularity could reflect, as in juvenile myelomonocytic leukemia cases, the presence of a larger number of multipotent progenitor cells. 
